This is best demonstrated in non-small cell lung cancer (NSCLC), where the identification of molecular alterations in driver genes, such as EGFR mutations, led to the approval and rapid development of the small molecule tyrosine kinase inhibitors (TKIs) [126]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.